Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...
Nano-X Imaging is a disruptive biotech investment. The AI push in the health sector is a long-term tailwind. See why we rate ...
19h
DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...
Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.
EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.
We recently compiled a list of the 10 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback